Prempro is a medication commonly prescribed for patients in need of hormone replacement therapy (HRT). The drug falls within a category of drugs known as progestins containing conjugated estrogens and medroxyprogesterone acetate.
When the ovaries stop making estrogens, menopause happens usually to women between 45-55 years old. This marks the end of monthly menstrual period or what is commonly referred to as the “change of life”.
Approximately three million women in the United States take Premarin (Prempro) daily to replace hormones lost at menopause. Every woman experiences menopause in a different way: Some may breeze through menopause without any noticeable changes while others experience hot flashes and intense sweating; vaginal atrophy where the lining of the vagina becomes dry, thinner, and less elastic making sexual intercourse extremely painful; irregular menstruation either with a very heavy flow, non-existent, and/or erratic; sleep disturbances and nightly sweats; and irritable mood swings.
Hormone replacement therapies (HRT) such as Premarin (Prempro) were prescribed as a means for reducing postmenopausal symptoms such as hot flashes and night sweats, vaginal itch and dryness, a propensity for developing osteoporosis and heart disease.
Premarin (Prempro) received FDA (Federal Drug Administration) approval as a HRT in 1995.
Monheit Law is investigating Prempro Cancer cases for long term users of Prempro who have developed either breast or ovarian cancer.
See: http://www.monheit.com/prempro/
